Literature DB >> 35107530

Prostate cancer mortality in Brazil 1990-2019: geographical distribution and trends.

Daniel Albrecht Iser1,2, Guilherme Ranzi Cobalchini2, Max Moura de Oliveira3, Renato Teixeira4, Deborah Carvalho Malta4, Mohsen Naghavi5, Betine Pinto Moehlecke Iser1.   

Abstract

INTRODUCTION: To analyze the trend of prostate cancer mortality in the Brazilian population of 40 years of age and above.
METHODS: Time series ecological study of the mortality rates due to prostate cancer in men of 40 years of age and above, using data from the Global Burden of Disease 2019 (GBD). Age-standardized mortality rates were calculated, as well as the age-standardized rates by the GBD for the global population, per 100,000 inhabitants, for Brazil and its States, from 1990 to 2019. The annual average percent change (AAPC) was calculated to identify the mortality trends in Brazil, through linear regression using the Joinpoint Regression Program.
RESULTS: The standardized rates of prostate cancer mortality in Brazil were 76.89 in 1990 and 74.96 deaths for every 100 thousand men ≥ 40 years of age in 2019, with a stability trend. By age group, it was observed a decreasing trend up to 79 years of age, and an increasing trend as of 80 years of age. The state of Bahia showed the highest increase in mortality in the period (1.2%/year), followed by Maranhão and Pernambuco (1.0 and 0.9%/year). A decrease of prostate cancer mortality was found in the Federal District, Goiás, Minas Gerais, Rio de Janeiro, Rio Grande do Sul, Roraima, Santa Catarina, São Paulo, and Sergipe.
CONCLUSIONS: In Brazil, the standardized mortality rates show a trend toward stability from 1990 to 2019 and no pattern was observed for the trends according to the Brazilian States.

Entities:  

Mesh:

Year:  2022        PMID: 35107530      PMCID: PMC9020381          DOI: 10.1590/0037-8682-0277-2021

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   2.141


INTRODUCTION

Prostate cancer is the second most commonly diagnosed cancer in men worldwide, with lung cancer being the first . There were 1.4 million new cases of this neoplasm in the world in 2020, with an incidence rate of 30.7 cases per 100,000, and 7.7 deaths per 100,000 inhabitants/year, totaling 375,000 deaths on a global scale. In Brazil alone, there were more than 18,000 deaths caused by the disease in 2020 . Age and family history are the main risk factors for prostate cancer. Other factors may include excessive consumption of lipids, as well as the consumption of alcohol and smoking, although there is no consensus in literature , - . Prostate cancer, in its early stages tends to be asymptomatic and has slow progress. In its advanced stages, it may manifest itself with symptoms in the lower urinary tract (LUT), microscopic hematuria, erectile dysfunction or nocturia, although those symptoms might occur due to benignant concomitant conditions or not , . Population screening of prostate cancer is still controversial . Its defenders base themselves on studies which show a relative reduction in specific cancer mortality of up to 9%, and explain this change with the introduction of prostate-specific antigen (PSA) monitoring , . Opponents base their opinions on systematic revisions, which show minimum or no impact on mortality and suggest that the risks and dangers of over-diagnosing and over-treatment outweigh the supposed modest benefits . The Brazilian Health Ministry and the National Cancer Institute do not recommend population screening for prostate cancer. Early detection should be performed for men who show symptoms related to the urinary tract or family history, and the risks inherent to the procedures should be discussed with the patient , . In Brazil, an analysis of the mortality trend of prostate cancer, from 1980 to 2010, using data from the Brazilian Mortality Information System (SIM, in Portuguese), demonstrated an increase in mortality for the male Brazilian population of over 40 years of age in all regions of the country. An increase of 7.7% in deaths was reported after the redistribution of the poorly defined causes of death . Further analysis with data up to 2014, and using a model of age-period-cohort, demonstrated an increase in mortality of men of 50 years of age and above over the last 30 years. Regional differences were identified, with a stable trend since 2004 in the South, Southeast, and Midwest regions, and an increase since 2000 in the North and Northeast regions. These trends might be related to access to health services for diagnosis and treatment. The significant effect of age was attributed mainly to population aging . However, an analysis from the previous trend, from 1996 to 2010, had projected a reduction in prostate cancer mortality for Brazil as a whole . Some of the diverging results from previous studies , , might be due to methodological differences and problems with the quality of the records of deaths according to the period and the place studied. The present study sought to understand the phenomenon of prostate cancer mortality in Brazil. With the availability of estimates from corrected data from the Global Burden of Diseases (GBD) study, this study seeks to analyze the trend of prostate cancer mortality in Brazil and its States, in men of 40 years of age and above.

METHODS

An ecological study was conducted, which considered all deaths by prostate cancer that occurred among males of 40 years of age or above in Brazil, from 1990 to 2019. Data corrected and estimated by the GBD was used - . GBD estimates of mortality used a multiple approach, mainly considering vital records (data from the Mortality Information System - SIM, in Brazil) and cancer registries , . The data reported were mapped to a list of underlying causes in the GBD causes of death hierarchy . Uninformative cause of death codes (the "garbage codes") are redistributed among appropriate underlying causes of death, as previously described , . Data on death were included in cancer-specific Cause of Death Ensemble models (CODEm) and were adjusted to independently modeled all-cause mortality (CodCorrect) . This study defined deaths by prostate cancer by all records of deaths, which informed the basic cause of pathology from chapter 2, Group C61 - Malignant Prostate Neoplasm according to the International Statistical Classification of Diseases and Related Health Problems (ICD)-10th Revision. Data about deaths was collected according to the year and the area considered, from the population of 40 years of age or above; specific rates were calculated for different age groups (40-49, 50-59, 60-69, 70-79, and 80+). Population data were obtained by GBD from the Brazilian Institute of Geography and Statistics (IBGE). Overall mortality was standardized by the direct method, by the standard global population provided by the GBD study . The crude and Age Standardized Mortality Rates (ASMR) were calculated per 100,000 inhabitants. Data was calculated for Brazil and its States. The average annual percent change (AAPC) was calculated to identify trends of mortality, with a 95% confidence interval (95% CI) and a significance level of 5%. The AAPC is the weighted average of the angular coefficients of the line of regression, with equal weight for the length of each segment in the entire interval. An increase or decrease in the trend is significant when different from zero (p<0.05) and stable when equal to zero (p> 0.05). The trend analysis was performed by linear regression, using the Joinpoint Regression Program, version 4.8.0.1 . The maps to represent trends for Brazil and its states were produced by QGIS 3.12. This study respected the ethical precepts for research and the specific Brazilian resolutions. It should be highlighted that the data was used in an aggregate format, without the identification of or harm to the individuals who participated in this study. The GBD study conforms to the guidelines for the reporting of precise and transparent health information.

RESULTS

For Brazil, the age-standardized rates went from 76.89 in 1990 to 74.96 deaths per 100,000 inhabitants, of 40 years of age or above in 2019, with a stable tendency in the studied time interval (Figure 1-2, Table 1 , Supplementary Table 1).
FIGURE 1:

Prostate Cancer Mortality Rate, according to age groups, Brazil, 1990-2019. AAPC: Average Annual Percentage Change; ASMR: Age Standardized Mortality Rate. *value of p <0.05

TABLE 1:

Standardized rate and average annual percentage of change (AAPC) of prostate cancer mortality in men ≥40 years of age, according State and year, 1990-2019.

StatesASMR
19902019AAPC95% CI
Acre84.0582.94-0.1(-0.4;0.1)
Alagoas66.0869.090.1(-0.1;0.3)
Amapá71.4776.340.2(-0.3;0.7)
Amazonas71.2076.550.2(-0.2;0.7)
Bahia72.54100.181.2*(1.0;1.4)
Ceará80.9878.87-0.1(-0.5;0.3)
Distrito Federal121.7984.94-1.3*(-1.7;-0.8)
Espírito Santo64.8277.060.6*(0.4;0.7)
Goiás82.3372.07-0.4*(-0.7;-0.2)
Maranhão71.8493.961.0*(0.2;1.7)
Mato Grosso79.7273.43-0.4(-0.8;0.1)
Mato Grosso do Sul73.5072.13-0.1(-0.2;0.1)
Minas Gerais72.5465.69-0.4*(-0.6;-0.2)
Pará64.3066.200.1(-0.1;0.4)
Paraíba73.3172.160.0(-0.7;0.7)
Paraná69.6577.530.4*(0.1;0.6)
Pernambuco68.7386.120.9*(0.6;1.1)
Piauí73.7465.25-0.4(-1.0;0.1)
Rio de Janeiro83.2178.16-0.2*(-0.4;-0.0)
Rio Grande do Norte66.0774.870.4*(0.2;0.6)
Rio Grande do Sul90.4476.72-0.6*(-0.7;-0.4)
Rondônia90.5981.52-0.2(-0.8;0.4)
Roraima119.2490.11-1.0*(-1.2;-0.7)
Santa Catarina77.7869.83-0.4*(-0.6;-0.1)
São Paulo81.2366.80-0.7*(-0.8;-0.5)
Sergipe98.6982.50-0.6*(-1.1;-0.2)
Tocantins78.1597.660.8*(0.0;1.6)
Brazil76.8974.96-0.1(-0.2;0.0)

ASMR: Age Standardized Mortality Rate according to age group distribution of the global population, shown in number of deaths per 100,000 inhabitants.CI: Confidence Interval. *p-value <0.05

The trend analysis identified that the state of Bahia showed the highest increase in mortality in the period (1.2 percentage point per year [p.p./year]), followed by Maranhão (1.0 p.p./year) and Pernambuco (0.9 p.p./year). Espírito Santo, Paraná, Rio Grande do Norte, and Tocantins showed an increasing trend but in lower proportion. A significant decrease in prostate cancer mortality was observed in the Federal District, Goiás, Minas Gerais, Rio de Janeiro, Rio Grande do Sul, Roraima, Santa Catarina, São Paulo, and Sergipe. The remaining states presented a stable tendency during the period, as did Brazil as a whole (Table 1, Figure 2 , Supplementary Table 1).
FIGURE 2:

Trend of prostate cancer mortality, according to age group, for Brazil and its states, 1990-2019. ASMR: Age Standardized Mortality Rate.

ASMR: Age Standardized Mortality Rate according to age group distribution of the global population, shown in number of deaths per 100,000 inhabitants.CI: Confidence Interval. *p-value <0.05 Among the studied age groups, for Brazil, the mortality rates showed a tendency of decrease between 40 and 79 years of age, and an increase for 80 years of age and older (0.2 p.p./year) (Table 2). No pattern in the trends was found for states according to age groups (Table 2 , Figure 2, Supplementary Tables 2-6). The increasing trend in Bahia and the decreasing trend in Rio Grande do Sul and São Paulo for men of 40 years of age and above stand out.
TABLE 2:

Prostate Cancer mortality rate (per 100,000 inhabitants) and average annual percentage of change (AAPC), according to age group, for Brazil and for its states, 1990 and 2019.

States40-49 years of age 50-59 years of age 60-69 years of age 70-79 years of age ≥80 years of age
19902019AAPC19902019AAPC19902019AAPC19902019AAPC19902019AAPC
Acre1.111.150.08.649.240.250.5352.320.1189.51209.650.4*798.72734.27-0.3
Alagoas1.251.280.19.109.640.154.3356,.340.1199.93192.25-0.1473.03527.110.3
Amapá0.911.070.57.708.850.5*47.5152.520.3*177.67208.530.5*632.28631.08-0.1
Amazonas1.071.150.28.949.210.255.5554.93-0.1197.77221.930.4557.75599.490.3
Bahia1.311.500.5*10.3713.791.0*61.8882.821.0*214.58284.501.0*519.81752.711.3*
Ceará1.331.23-0.3*10.449.87-0.259.8253.38-0.4*240.18207.52-0.5*614.75665.780.3
Distrito Federal1.240.94-1.0*10.467.68-1.1*67.9650.00-1.0*281.24206.39-1.0*1173.27788.52-1.3*
Espírito Santo1.051.110.28.759.270.253.8550.66-0.3*184.54207.430.4*485.67648.741.0*
Goiás1.501.10-1.0*12.128.81-1.1*69.8754.31-0.9*240.80199.01-0.7*594.57574.04-0.1
Maranhão1.311.25-0.29.8411.170.5*57.3766.680.5*195.24234.180.7*561.63811.371.5*
Mato Grosso1.211.18-0.09.809.46-0.157.6853.03-0.3242.55210.26-0.5600.44575.62-0.2
Mato Grosso do Sul1.221.15-0.29.769.04-0.360.6350.47-0.6*216.45194.08-0.4*539.15595.280.4*
Minas Gerais1.191.17-0.010.529.45-0.4*57.7050.68-0.5*212.38181.80-0.5*537.46511.35-0.2
Pará1.001.040.18.828.39-0.250.8850.880.0193.47188.16-0.1470.04512.500.3
Paraíba1.241.270.19.8610.370.257.5557.37-0.0214.77194.96-0.4548.65565.240.1
Paraná1.031.060.19.229.180.056.6454.47-0.1196.60213.370.3530.30633.580.6*
Pernambuco1.221.350.39.4311.410.6*59.9462.450.2200.10241.070.7*496.23683.471.1*
Piauí1.151.09-0.29.178.67-0.258.4352.28-0.4*216.55174.78-0.8*552.93516.21-0.3
Rio de Janeiro1.401.15-0.7*12.3010.63-0.5*70.7060.47-0.5*250.56217.28-0.5*587.64610.120.2
Rio Grande do Norte1.121.160.28.079.130.552.3752.55-0.0189.85202.050.2503.30617.640.7*
Rio Grande do Sul1.281.07-0.6*12.448.77-1.2*70.4255.46-0.8*265.72210.49-0.8*677.42624.47-0.3*
Rondônia1.321.25-0.19.899.49-0.157.3960.940.2241.24226.78-0.1778.89649.77-0.4
Roraima1.471.26-0.611.2211.12-0.082.6163.38-0.9*306.87225.94-1.0*1031.91775.39-1.0*
Santa Catarina1.030.97-0.29.618.24-0.6*61.4247.42-0.9*216.72190.22-0.4*607.15579.71-0.2
São Paulo1.211.03-0.5*11.038.57-0.9*65.3950.40-0.9*239.00179.37-1.0*601.08539.55-0.4*
Sergipe1.451.40-0.111.8311.21-0.269.3760.85-0.4*245.49236.88-0.1854.10638.43-1.3*
Tocantins1.181.320.48.8910.980.7*56.2865.460.5*193.04234.920.7*676.53874.430.9*
Brazil1.231.15-0.2*10.629.62-0.3*62.4555.75-0.4*224.71204.98-0.3*568.71601.060.2*

*p-value <0.05.

*p-value <0.05.

DISCUSSION

This study evaluates the trends of prostate cancer mortality in Brazil and its states, from 1990 to 2019. The results show that mortality, corrected by the GBD, was stable in Brazil. However, according to the Brazilian states, disparities were observed. Although stability can be found in the mortality rates in most of the states of Brazil, with no specific regional pattern, the corrected mortality for the initial year (1990) and final year (2019) in the series make the states of Bahia, Maranhão, and Tocantins (from the Northeast and North regions of Brazil) stand out due to the highest rates identified at the end of the series, and the highest increase during the period. By contrast, of the nine states with a trend leaning toward a reduction in mortality, seven are in the Midwest, Southeast, and South regions of the country. Such diversities match the estimates projected for 2025, with data from 2010 , suggesting that the highest mortality in the less developed regions was related to a limited access to diagnosis and treatment, as well as to the lower quality of health services and information. Such inequalities were also indicated in other national studies , , including differences between the capitals and the more outlying regions of the country . One can consider that the improvement in life expectancy in some of the Brazilian states, such as Bahia, may not be accompanied by healthier habits, nor access to health services and preventive education. The population, urbanized and older, fall ill more often and, with a more delayed diagnosis, ends up dying because of the disease. States, such as Rio Grande do Sul and São Paulo, where conditions of access to health and educational and income standards are higher, when compared to states from the North and Northeastern regions of the country, demonstrate a trend toward a decrease in mortality for all age groups . When data is separated by age group, mortality in Brazil tends to be higher for those people of 80 years of age and above, and stable before that age, which is consistent with findings from the literature, which describes prostate cancer as a disease of elderly men . However, this goes against what has been happening in other countries, such as in some European countries , and in North America , which show a decrease in mortality in the last years of analysis; in China as well, where mortality has decreased between 1990 and 2017 for people 40 years of age and above . Among the South American countries (Argentina, Brazil, Chile, Colombia, Cuba, Mexico, and Venezuela), a tendency of decrease in prostate cancer mortality of men was estimated at every age, between 2012 and 2017 . Regardless of the identified trends, a study based on the GBD, which evaluated mortality by cancer around the world, indicated that prostate cancer was the most prevalent cancer in 114 countries in 2017, and the main cause of death by cancer, for men in 56 countries . Other factors, such as the successful screening of the studied neoplasm, may have contributed to improved records of mortality . International studies indicate that the reduction in prostate cancer mortality is due to increased screening , , , as well as to improvements in the treatments for the disease . Measures of population screening are not recommended in Brazil because of the limited evidence of cost-benefit, due to the possibility of overdiagnosis , , . Therefore, the diagnostic exams are performed on demand, and it is expected that they will be more frequent in places where there is more interest and access to health services. It is well-known that the spontaneous interest for health services on the part of the male population is low . Studies indicate that in some parts of the country, less than 50% of men seek medical attention. When it does happen, the interest is mainly due to the presence of already evident symptoms or due to an urgent need , . Nevertheless, tendency studies indicate an increase in the number of men who sought out health services from 2008 to 2013 in Brazil, especially in the Southeast and South regions . This may have contributed to a reduction in mortality verified in some states in those regions. The Ministry of Health’s creation of the national policy of overall attention to the health of men, formulated in 2009, aims to provide more attention and health education to the male population at the primary level of attention to health, which may improve inclusion and, consequently, impact mortality due to prostate cancer . The effect of the differences in lifestyles among countries should also be considered, and in the trend analysis, the changes in terms of exposure to risk factors related to susceptibility and cancer mortality, although there is no consensus in literature on this issue , . Although there has been a reduction in smoking and an increase in physical activity and consumption of fruits and vegetables among Brazilian men, up to 2019, the prevalence of excessive weight and obesity was still increasing , which may have had implications in the development of this cancer. Smoking is one of the main risk factors associated with prostate cancer and it has been connected to the high incidence of prostate cancer , , . Besides being one of the most common risk factors for the development of cancer, the habit of smoking at the time of diagnosis and treatment of the disease demonstrated, in a meta-analysis, a negative impact on the patient's prognosis, which is associated with a lower survival rate . Regardless of the decreasing trend verified in Brazil , it is estimated that 15.9% of Brazilian men are smokers, especially in the Southeast and South regions , which is an important factor to be addressed in the prevention of prostate cancer . The identification of a stable trend in prostate cancer mortality, differently from the findings of different studies which show an increase in mortality in Brazil and its regions, may be related to differences in the methodologies used in the publications , , . The evaluation of causes of death and trends from 1990 to 2019 for Brazil may be affected by the quality of data and by changes in the information systems in the period of each study. Therefore, the use of secondary data, which reports deaths without an adequate record of causes, influenced by the lack of a precise diagnosis, may be considered an overall limitation in the studies of mortality. The comparisons between the estimates from different studies must be performed carefully, considering such specificities. The use of corrected data and the redistribution of garbage codes , obtained from the GBD study, bring the data closer to reality. This happens because the GBD study tries to minimize the lack of secondary data and its low quality by using diverse sources, such as verbal records of cancer and autopsy. It also adjusts the estimates, with correction for the poorly defined causes of death. The present study highlights that, since it uses a globally standardized methodology, the study has the potential of allowing comparisons of mortality between different Brazilian states and regions, as well as between Brazil and other countries. Mortality by prostate cancer in men 40 years of age and above, in Brazil, has remained stable in the period of 1990 to 2019, with an increase in the population of 80 years of age and above, and with regional differences, which proved to be more prevalent in states from the Northeast and North regions. The heterogeneity found in this study may be a reflection of economic factors, of education, and of access to health care, for both early diagnosis and adequate treatment.
  40 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Prevalence and factors associated with the use of public health services for adult men.

Authors:  Guilherme Oliveira de Arruda; Thais Aidar de Freitas Mathias; Sonia Silva Marcon
Journal:  Cien Saude Colet       Date:  2017-01

3.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  David C Grossman; Susan J Curry; Douglas K Owens; Kirsten Bibbins-Domingo; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; Mark Ebell; John W Epling; Alex R Kemper; Alex H Krist; Martha Kubik; C Seth Landefeld; Carol M Mangione; Michael Silverstein; Melissa A Simon; Albert L Siu; Chien-Wen Tseng
Journal:  JAMA       Date:  2018-05-08       Impact factor: 56.272

Review 4.  Primary Care of the Prostate Cancer Survivor.

Authors:  Erika M Noonan; Timothy W Farrell
Journal:  Am Fam Physician       Date:  2016-05-01       Impact factor: 3.292

5.  Has prostate cancer mortality stopped its decline in Spain?

Authors:  A Cayuela; L Cayuela; M V Ruiz-Romero; S Rodríguez-Domínguez; G Lendínez-Cano; J Bachiller-Burgos
Journal:  Actas Urol Esp       Date:  2015-07-09       Impact factor: 0.994

6.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

7.  Tendencies of mortality by prostate cancer in the states of the Central-West Region of Brazil, 1980-2011.

Authors:  João Francisco Santos da Silva; Inês Echenique Mattos; Ricardo Dutra Aydos
Journal:  Rev Bras Epidemiol       Date:  2014 Apr-Jun

8.  Magnitude and variation of the burden of cancer mortality in Brazil and Federation Units, 1990 and 2015.

Authors:  Maximiliano Ribeiro Guerra; Maria Teresa Bustamante-Teixeira; Camila Soares Lima Corrêa; Daisy Maria Xavier de Abreu; Maria Paula Curado; Meghan Mooney; Mohsen Naghavi; Renato Teixeira; Elisabeth Barboza França; Deborah Carvalho Malta
Journal:  Rev Bras Epidemiol       Date:  2017-05

9.  Cancer mortality in the Capitals and in the interior of Brazil: a four-decade analysis.

Authors:  Gulnar Azevedo E Silva; Beatriz Cordeiro Jardim; Vanessa de Melo Ferreira; Washington Leite Junger; Vania Reis Girianelli
Journal:  Rev Saude Publica       Date:  2020-12-04       Impact factor: 2.106

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Degu Abate; Naghmeh Abbasi; Hedayat Abbastabar; Foad Abd-Allah; Omar Abdel-Rahman; Ahmed Abdelalim; Amir Abdoli; Ibrahim Abdollahpour; Abdishakur S M Abdulle; Nebiyu Dereje Abebe; Haftom Niguse Abraha; Laith Jamal Abu-Raddad; Ahmed Abualhasan; Isaac Akinkunmi Adedeji; Shailesh M Advani; Mohsen Afarideh; Mahdi Afshari; Mohammad Aghaali; Dominic Agius; Sutapa Agrawal; Ayat Ahmadi; Elham Ahmadian; Ehsan Ahmadpour; Muktar Beshir Ahmed; Mohammad Esmaeil Akbari; Tomi Akinyemiju; Ziyad Al-Aly; Assim M AlAbdulKader; Fares Alahdab; Tahiya Alam; Genet Melak Alamene; Birhan Tamene T Alemnew; Kefyalew Addis Alene; Cyrus Alinia; Vahid Alipour; Syed Mohamed Aljunid; Fatemeh Allah Bakeshei; Majid Abdulrahman Hamad Almadi; Amir Almasi-Hashiani; Ubai Alsharif; Shirina Alsowaidi; Nelson Alvis-Guzman; Erfan Amini; Saeed Amini; Yaw Ampem Amoako; Zohreh Anbari; Nahla Hamed Anber; Catalina Liliana Andrei; Mina Anjomshoa; Fereshteh Ansari; Ansariadi Ansariadi; Seth Christopher Yaw Appiah; Morteza Arab-Zozani; Jalal Arabloo; Zohreh Arefi; Olatunde Aremu; Habtamu Abera Areri; Al Artaman; Hamid Asayesh; Ephrem Tsegay Asfaw; Alebachew Fasil Ashagre; Reza Assadi; Bahar Ataeinia; Hagos Tasew Atalay; Zerihun Ataro; Suleman Atique; Marcel Ausloos; Leticia Avila-Burgos; Euripide F G A Avokpaho; Ashish Awasthi; Nefsu Awoke; Beatriz Paulina Ayala Quintanilla; Martin Amogre Ayanore; Henok Tadesse Ayele; Ebrahim Babaee; Umar Bacha; Alaa Badawi; Mojtaba Bagherzadeh; Eleni Bagli; Senthilkumar Balakrishnan; Abbas Balouchi; Till Winfried Bärnighausen; Robert J Battista; Masoud Behzadifar; Meysam Behzadifar; Bayu Begashaw Bekele; Yared Belete Belay; Yaschilal Muche Belayneh; Kathleen Kim Sachiko Berfield; Adugnaw Berhane; Eduardo Bernabe; Mircea Beuran; Nickhill Bhakta; Krittika Bhattacharyya; Belete Biadgo; Ali Bijani; Muhammad Shahdaat Bin Sayeed; Charles Birungi; Catherine Bisignano; Helen Bitew; Tone Bjørge; Archie Bleyer; Kassawmar Angaw Bogale; Hunduma Amensisa Bojia; Antonio M Borzì; Cristina Bosetti; Ibrahim R Bou-Orm; Hermann Brenner; Jerry D Brewer; Andrey Nikolaevich Briko; Nikolay Ivanovich Briko; Maria Teresa Bustamante-Teixeira; Zahid A Butt; Giulia Carreras; Juan J Carrero; Félix Carvalho; Clara Castro; Franz Castro; Ferrán Catalá-López; Ester Cerin; Yazan Chaiah; Wagaye Fentahun Chanie; Vijay Kumar Chattu; Pankaj Chaturvedi; Neelima Singh Chauhan; Mohammad Chehrazi; Peggy Pei-Chia Chiang; Tesfaye Yitna Chichiabellu; Onyema Greg Chido-Amajuoyi; Odgerel Chimed-Ochir; Jee-Young J Choi; Devasahayam J Christopher; Dinh-Toi Chu; Maria-Magdalena Constantin; Vera M Costa; Emanuele Crocetti; Christopher Stephen Crowe; Maria Paula Curado; Saad M A Dahlawi; Giovanni Damiani; Amira Hamed Darwish; Ahmad Daryani; José das Neves; Feleke Mekonnen Demeke; Asmamaw Bizuneh Demis; Birhanu Wondimeneh Demissie; Gebre Teklemariam Demoz; Edgar Denova-Gutiérrez; Afshin Derakhshani; Kalkidan Solomon Deribe; Rupak Desai; Beruk Berhanu Desalegn; Melaku Desta; Subhojit Dey; Samath Dhamminda Dharmaratne; Meghnath Dhimal; Daniel Diaz; Mesfin Tadese Tadese Dinberu; Shirin Djalalinia; David Teye Doku; Thomas M Drake; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Hedyeh Ebrahimi; Andem Effiong; Aziz Eftekhari; Iman El Sayed; Maysaa El Sayed Zaki; Shaimaa I El-Jaafary; Ziad El-Khatib; Demelash Abewa Elemineh; Hajer Elkout; Richard G Ellenbogen; Aisha Elsharkawy; Mohammad Hassan Emamian; Daniel Adane Endalew; Aman Yesuf Endries; Babak Eshrati; Ibtihal Fadhil; Vahid Fallah Omrani; Mahbobeh Faramarzi; Mahdieh Abbasalizad Farhangi; Andrea Farioli; Farshad Farzadfar; Netsanet Fentahun; Eduarda Fernandes; Garumma Tolu Feyissa; Irina Filip; Florian Fischer; James L Fisher; Lisa M Force; Masoud Foroutan; Marisa Freitas; Takeshi Fukumoto; Neal D Futran; Silvano Gallus; Fortune Gbetoho Gankpe; Reta Tsegaye Gayesa; Tsegaye Tewelde Gebrehiwot; Gebreamlak Gebremedhn Gebremeskel; Getnet Azeze Gedefaw; Belayneh K Gelaw; Birhanu Geta; Sefonias Getachew; Kebede Embaye Gezae; Mansour Ghafourifard; Alireza Ghajar; Ahmad Ghashghaee; Asadollah Gholamian; Paramjit Singh Gill; Themba T G Ginindza; Alem Girmay; Muluken Gizaw; Ricardo Santiago Gomez; Sameer Vali Gopalani; Giuseppe Gorini; Bárbara Niegia Garcia Goulart; Ayman Grada; Maximiliano Ribeiro Guerra; Andre Luiz Sena Guimaraes; Prakash C Gupta; Rahul Gupta; Kishor Hadkhale; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Randah R Hamadeh; Samer Hamidi; Lolemo Kelbiso Hanfore; Josep Maria Haro; Milad Hasankhani; Amir Hasanzadeh; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Andualem Henok; Nathaniel J Henry; Claudiu Herteliu; Hagos D Hidru; Chi Linh Hoang; Michael K Hole; Praveen Hoogar; Nobuyuki Horita; H Dean Hosgood; Mostafa Hosseini; Mehdi Hosseinzadeh; Mihaela Hostiuc; Sorin Hostiuc; Mowafa Househ; Mohammedaman Mama Hussen; Bogdan Ileanu; Milena D Ilic; Kaire Innos; Seyed Sina Naghibi Irvani; Kufre Robert Iseh; Sheikh Mohammed Shariful Islam; Farhad Islami; Nader Jafari Balalami; Morteza Jafarinia; Leila Jahangiry; Mohammad Ali Jahani; Nader Jahanmehr; Mihajlo Jakovljevic; Spencer L James; Mehdi Javanbakht; Sudha Jayaraman; Sun Ha Jee; Ensiyeh Jenabi; Ravi Prakash Jha; Jost B Jonas; Jitendra Jonnagaddala; Tamas Joo; Suresh Banayya Jungari; Mikk Jürisson; Ali Kabir; Farin Kamangar; André Karch; Narges Karimi; Ansar Karimian; Amir Kasaeian; Gebremicheal Gebreslassie Kasahun; Belete Kassa; Tesfaye Dessale Kassa; Mesfin Wudu Kassaw; Anil Kaul; Peter Njenga Keiyoro; Abraham Getachew Kelbore; Amene Abebe Kerbo; Yousef Saleh Khader; Maryam Khalilarjmandi; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Khaled Khatab; Amir Khater; Maryam Khayamzadeh; Maryam Khazaee-Pool; Salman Khazaei; Abdullah T Khoja; Mohammad Hossein Khosravi; Jagdish Khubchandani; Neda Kianipour; Daniel Kim; Yun Jin Kim; Adnan Kisa; Sezer Kisa; Katarzyna Kissimova-Skarbek; Hamidreza Komaki; Ai Koyanagi; Kristopher J Krohn; Burcu Kucuk Bicer; Nuworza Kugbey; Vivek Kumar; Desmond Kuupiel; Carlo La Vecchia; Deepesh P Lad; Eyasu Alem Lake; Ayenew Molla Lakew; Dharmesh Kumar Lal; Faris Hasan Lami; Qing Lan; Savita Lasrado; Paolo Lauriola; Jeffrey V Lazarus; James Leigh; Cheru Tesema Leshargie; Yu Liao; Miteku Andualem Limenih; Stefan Listl; Alan D Lopez; Platon D Lopukhov; Raimundas Lunevicius; Mohammed Madadin; Sameh Magdeldin; Hassan Magdy Abd El Razek; Azeem Majeed; Afshin Maleki; Reza Malekzadeh; Ali Manafi; Navid Manafi; Wondimu Ayele Manamo; Morteza Mansourian; Mohammad Ali Mansournia; Lorenzo Giovanni Mantovani; Saman Maroufizadeh; Santi Martini S Martini; Tivani Phosa Mashamba-Thompson; Benjamin Ballard Massenburg; Motswadi Titus Maswabi; Manu Raj Mathur; Colm McAlinden; Martin McKee; Hailemariam Abiy Alemu Meheretu; Ravi Mehrotra; Varshil Mehta; Toni Meier; Yohannes A Melaku; Gebrekiros Gebremichael Meles; Hagazi Gebre Meles; Addisu Melese; Mulugeta Melku; Peter T N Memiah; Walter Mendoza; Ritesh G Menezes; Shahin Merat; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Tomasz Miazgowski; Kebadnew Mulatu M Mihretie; Ted R Miller; Edward J Mills; Seyed Mostafa Mir; Hamed Mirzaei; Hamid Reza Mirzaei; Rashmi Mishra; Babak Moazen; Dara K Mohammad; Karzan Abdulmuhsin Mohammad; Yousef Mohammad; Aso Mohammad Darwesh; Abolfazl Mohammadbeigi; Hiwa Mohammadi; Moslem Mohammadi; Mahdi Mohammadian; Abdollah Mohammadian-Hafshejani; Milad Mohammadoo-Khorasani; Reza Mohammadpourhodki; Ammas Siraj Mohammed; Jemal Abdu Mohammed; Shafiu Mohammed; Farnam Mohebi; Ali H Mokdad; Lorenzo Monasta; Yoshan Moodley; Mahmood Moosazadeh; Maryam Moossavi; Ghobad Moradi; Mohammad Moradi-Joo; Maziar Moradi-Lakeh; Farhad Moradpour; Lidia Morawska; Joana Morgado-da-Costa; Naho Morisaki; Shane Douglas Morrison; Abbas Mosapour; Seyyed Meysam Mousavi; Achenef Asmamaw Muche; Oumer Sada S Muhammed; Jonah Musa; Ashraf F Nabhan; Mehdi Naderi; Ahamarshan Jayaraman Nagarajan; Gabriele Nagel; Azin Nahvijou; Gurudatta Naik; Farid Najafi; Luigi Naldi; Hae Sung Nam; Naser Nasiri; Javad Nazari; Ionut Negoi; Subas Neupane; Polly A Newcomb; Haruna Asura Nggada; Josephine W Ngunjiri; Cuong Tat Nguyen; Leila Nikniaz; Dina Nur Anggraini Ningrum; Yirga Legesse Nirayo; Molly R Nixon; Chukwudi A Nnaji; Marzieh Nojomi; Shirin Nosratnejad; Malihe Nourollahpour Shiadeh; Mohammed Suleiman Obsa; Richard Ofori-Asenso; Felix Akpojene Ogbo; In-Hwan Oh; Andrew T Olagunju; Tinuke O Olagunju; Mojisola Morenike Oluwasanu; Abidemi E Omonisi; Obinna E Onwujekwe; Anu Mary Oommen; Eyal Oren; Doris D V Ortega-Altamirano; Erika Ota; Stanislav S Otstavnov; Mayowa Ojo Owolabi; Mahesh P A; Jagadish Rao Padubidri; Smita Pakhale; Amir H Pakpour; Adrian Pana; Eun-Kee Park; Hadi Parsian; Tahereh Pashaei; Shanti Patel; Snehal T Patil; Alyssa Pennini; David M Pereira; Cristiano Piccinelli; Julian David Pillay; Majid Pirestani; Farhad Pishgar; Maarten J Postma; Hadi Pourjafar; Farshad Pourmalek; Akram Pourshams; Swayam Prakash; Narayan Prasad; Mostafa Qorbani; Mohammad Rabiee; Navid Rabiee; Amir Radfar; Alireza Rafiei; Fakher Rahim; Mahdi Rahimi; Muhammad Aziz Rahman; Fatemeh Rajati; Saleem M Rana; Samira Raoofi; Goura Kishor Rath; David Laith Rawaf; Salman Rawaf; Robert C Reiner; Andre M N Renzaho; Nima Rezaei; Aziz Rezapour; Ana Isabel Ribeiro; Daniela Ribeiro; Luca Ronfani; Elias Merdassa Roro; Gholamreza Roshandel; Ali Rostami; Ragy Safwat Saad; Parisa Sabbagh; Siamak Sabour; Basema Saddik; Saeid Safiri; Amirhossein Sahebkar; Mohammad Reza Salahshoor; Farkhonde Salehi; Hosni Salem; Marwa Rashad Salem; Hamideh Salimzadeh; Joshua A Salomon; Abdallah M Samy; Juan Sanabria; Milena M Santric Milicevic; Benn Sartorius; Arash Sarveazad; Brijesh Sathian; Maheswar Satpathy; Miloje Savic; Monika Sawhney; Mehdi Sayyah; Ione J C Schneider; Ben Schöttker; Mario Sekerija; Sadaf G Sepanlou; Masood Sepehrimanesh; Seyedmojtaba Seyedmousavi; Faramarz Shaahmadi; Hosein Shabaninejad; Mohammad Shahbaz; Masood Ali Shaikh; Amir Shamshirian; Morteza Shamsizadeh; Heidar Sharafi; Zeinab Sharafi; Mehdi Sharif; Ali Sharifi; Hamid Sharifi; Rajesh Sharma; Aziz Sheikh; Reza Shirkoohi; Sharvari Rahul Shukla; Si Si; Soraya Siabani; Diego Augusto Santos Silva; Dayane Gabriele Alves Silveira; Ambrish Singh; Jasvinder A Singh; Solomon Sisay; Freddy Sitas; Eugène Sobngwi; Moslem Soofi; Joan B Soriano; Vasiliki Stathopoulou; Mu'awiyyah Babale Sufiyan; Rafael Tabarés-Seisdedos; Takahiro Tabuchi; Ken Takahashi; Omid Reza Tamtaji; Mohammed Rasoul Tarawneh; Segen Gebremeskel Tassew; Parvaneh Taymoori; Arash Tehrani-Banihashemi; Mohamad-Hani Temsah; Omar Temsah; Berhe Etsay Tesfay; Fisaha Haile Tesfay; Manaye Yihune Teshale; Gizachew Assefa Tessema; Subash Thapa; Kenean Getaneh Tlaye; Roman Topor-Madry; Marcos Roberto Tovani-Palone; Eugenio Traini; Bach Xuan Tran; Khanh Bao Tran; Afewerki Gebremeskel Tsadik; Irfan Ullah; Olalekan A Uthman; Marco Vacante; Maryam Vaezi; Patricia Varona Pérez; Yousef Veisani; Simone Vidale; Francesco S Violante; Vasily Vlassov; Stein Emil Vollset; Theo Vos; Kia Vosoughi; Giang Thu Vu; Isidora S Vujcic; Henry Wabinga; Tesfahun Mulatu Wachamo; Fasil Shiferaw Wagnew; Yasir Waheed; Fitsum Weldegebreal; Girmay Teklay Weldesamuel; Tissa Wijeratne; Dawit Zewdu Wondafrash; Tewodros Eshete Wonde; Adam Belay Wondmieneh; Hailemariam Mekonnen Workie; Rajaram Yadav; Abbas Yadegar; Ali Yadollahpour; Mehdi Yaseri; Vahid Yazdi-Feyzabadi; Alex Yeshaneh; Mohammed Ahmed Yimam; Ebrahim M Yimer; Engida Yisma; Naohiro Yonemoto; Mustafa Z Younis; Bahman Yousefi; Mahmoud Yousefifard; Chuanhua Yu; Erfan Zabeh; Vesna Zadnik; Telma Zahirian Moghadam; Zoubida Zaidi; Mohammad Zamani; Hamed Zandian; Alireza Zangeneh; Leila Zaki; Kazem Zendehdel; Zerihun Menlkalew Zenebe; Taye Abuhay Zewale; Arash Ziapour; Sanjay Zodpey; Christopher J L Murray
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.